We re-evaluated a comprehensive data set of CYP2D6 genotypes and TAM metabolite concentrations of breast cancer patients treated with adjuvant TAM to assess the prediction of impaired TAM metabolism by CYP2D6. The gene discussed is CYP2D6; the disease is breast carcinoma.